Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

MAZE

+ Watchlist+ Portfolio

Maze Therapeutics, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$31.20
52-Week Range
$21.95 – $53.65
Market Cap
$1.77B
P/E (TTM)
—
EPS (TTM)
-2.62
Dividend Yield
0.00%
Advanced Metrics
Price/Book
4.27
PEG Ratio
—
Return on Equity
-37.49%
Return on Assets
-21.98%
Gross Margin
100.00%
Operating Margin
-820.82%
Profit Margin
0.00%
Current Ratio
14.14
Debt/Equity
0.14
Total Debt
$59.64M
Free Cash Flow
$-68.62M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$1.38B

Market Snapshot

About

Maze Therapeutics is a genetic medicine biotechnology company developing therapies based on insights from human genetics. The company focuses on common and rare diseases with validated genetic targets.